Cargando…

Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus

The clinical symptoms of COVID-19 infection differ from one patient to another, requiring different management. This study intended to characterize the clinical manifestation of COVID-19 in patients with asthma, hypertension, and diabetes mellitus (DM). We analyzed data from 540 medical records of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Budiarti, Retno, Ediono, Ediono, Kalaznykov, Mohammad, Yamaoka, Yoshio, Miftahussurur, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884347/
https://www.ncbi.nlm.nih.gov/pubmed/36762324
http://dx.doi.org/10.25122/jml-2021-0364
_version_ 1784879697775034368
author Budiarti, Retno
Ediono, Ediono
Kalaznykov, Mohammad
Yamaoka, Yoshio
Miftahussurur, Muhammad
author_facet Budiarti, Retno
Ediono, Ediono
Kalaznykov, Mohammad
Yamaoka, Yoshio
Miftahussurur, Muhammad
author_sort Budiarti, Retno
collection PubMed
description The clinical symptoms of COVID-19 infection differ from one patient to another, requiring different management. This study intended to characterize the clinical manifestation of COVID-19 in patients with asthma, hypertension, and diabetes mellitus (DM). We analyzed data from 540 medical records of patients with comorbidities like asthma, hypertension, and DM diagnosed with COVID-19, looking at vital signs upon admission, chest X-ray, and laboratory results. Most patients were male (57.0%). The most prevalent comorbidity was hypertension (46.3%) and DM (46.3%), followed by asthma (7.4%). 273 patients had improved condition (50.6%). Patients with hypertension had the most extended length of stay compared to other comorbidities groups (13.0±8.5 days). There were significant differences in the oxygen saturation and respiration rate between the three groups (p=0.002, p<0.0001, respectively). The mean lymphocyte (p=0.028) and hematocrit count (p=0.001) were significantly different between the three comorbid groups, with the hypertension group having the highest mean lymphocyte (15.1±8.9) and hematocrit (38.7±6.9) count. COVID-19 had a significant impact on patients with asthma, hypertension, and diabetes comorbidities concerning the final condition, length of stay, oxygen saturation, and respiratory rate, and also on the hematology level, mainly lymphocyte and hematocrit. Treatment, age, and infection might be determinant factors for different outcomes in each type of comorbidity.
format Online
Article
Text
id pubmed-9884347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-98843472023-02-08 Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus Budiarti, Retno Ediono, Ediono Kalaznykov, Mohammad Yamaoka, Yoshio Miftahussurur, Muhammad J Med Life Original Article The clinical symptoms of COVID-19 infection differ from one patient to another, requiring different management. This study intended to characterize the clinical manifestation of COVID-19 in patients with asthma, hypertension, and diabetes mellitus (DM). We analyzed data from 540 medical records of patients with comorbidities like asthma, hypertension, and DM diagnosed with COVID-19, looking at vital signs upon admission, chest X-ray, and laboratory results. Most patients were male (57.0%). The most prevalent comorbidity was hypertension (46.3%) and DM (46.3%), followed by asthma (7.4%). 273 patients had improved condition (50.6%). Patients with hypertension had the most extended length of stay compared to other comorbidities groups (13.0±8.5 days). There were significant differences in the oxygen saturation and respiration rate between the three groups (p=0.002, p<0.0001, respectively). The mean lymphocyte (p=0.028) and hematocrit count (p=0.001) were significantly different between the three comorbid groups, with the hypertension group having the highest mean lymphocyte (15.1±8.9) and hematocrit (38.7±6.9) count. COVID-19 had a significant impact on patients with asthma, hypertension, and diabetes comorbidities concerning the final condition, length of stay, oxygen saturation, and respiratory rate, and also on the hematology level, mainly lymphocyte and hematocrit. Treatment, age, and infection might be determinant factors for different outcomes in each type of comorbidity. Carol Davila University Press 2022-12 /pmc/articles/PMC9884347/ /pubmed/36762324 http://dx.doi.org/10.25122/jml-2021-0364 Text en ©2022 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Original Article
Budiarti, Retno
Ediono, Ediono
Kalaznykov, Mohammad
Yamaoka, Yoshio
Miftahussurur, Muhammad
Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus
title Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus
title_full Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus
title_fullStr Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus
title_full_unstemmed Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus
title_short Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus
title_sort clinical manifestations of covid-19 in patients with asthma, hypertension, and diabetes mellitus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884347/
https://www.ncbi.nlm.nih.gov/pubmed/36762324
http://dx.doi.org/10.25122/jml-2021-0364
work_keys_str_mv AT budiartiretno clinicalmanifestationsofcovid19inpatientswithasthmahypertensionanddiabetesmellitus
AT edionoediono clinicalmanifestationsofcovid19inpatientswithasthmahypertensionanddiabetesmellitus
AT kalaznykovmohammad clinicalmanifestationsofcovid19inpatientswithasthmahypertensionanddiabetesmellitus
AT yamaokayoshio clinicalmanifestationsofcovid19inpatientswithasthmahypertensionanddiabetesmellitus
AT miftahussururmuhammad clinicalmanifestationsofcovid19inpatientswithasthmahypertensionanddiabetesmellitus